Comparative effects of oral hypoglycemic drugs on serum YKL-40 level in type 2 diabetic patients.
Matta, C., Abdel- Rahim, M., Youssri, M., Wazeery, A. (2020). Comparative effects of oral hypoglycemic drugs on serum YKL-40 level in type 2 diabetic patients.. EKB Journal Management System, 3(2), 41-47. doi: 10.21608/svuijm.2020.111904
Caterine N. Matta; Mahmoud H. Abdel- Rahim; Magda M. Youssri; Abdulhakim E. Mustafa Wazeery. "Comparative effects of oral hypoglycemic drugs on serum YKL-40 level in type 2 diabetic patients.". EKB Journal Management System, 3, 2, 2020, 41-47. doi: 10.21608/svuijm.2020.111904
Matta, C., Abdel- Rahim, M., Youssri, M., Wazeery, A. (2020). 'Comparative effects of oral hypoglycemic drugs on serum YKL-40 level in type 2 diabetic patients.', EKB Journal Management System, 3(2), pp. 41-47. doi: 10.21608/svuijm.2020.111904
Matta, C., Abdel- Rahim, M., Youssri, M., Wazeery, A. Comparative effects of oral hypoglycemic drugs on serum YKL-40 level in type 2 diabetic patients.. EKB Journal Management System, 2020; 3(2): 41-47. doi: 10.21608/svuijm.2020.111904

Comparative effects of oral hypoglycemic drugs on serum YKL-40 level in type 2 diabetic patients.

SVU-International Journal of Medical Sciences
Article 8, Volume 3, Issue 2, July 2020, Page 41-47  XML PDF (196.91 K)
Document Type: Original research articles
DOI: 10.21608/svuijm.2020.111904
View on SCiNiTO View on SCiNiTO
Authors
Caterine N. Matta* 1; Mahmoud H. Abdel- Rahim2; Magda M. Youssri3; Abdulhakim E. Mustafa Wazeery4
1Medical pharmacologydepartment, QenaFaculty of Medicine, SouthValley University.
2Medical pharmacology department, Faculty of Medicine, Assiut University
3Medical pharmacology department, Faculty of Medicine, Assiut University.
4Internal Medicine department, Qena Faculty of Medicine, South Valley University
Abstract
Background:The prevalence of Type 2 diabetes mellitus and its associated micro and macro-vascular complications are globally rapidly increasing. Studies show that most diabetic complications are associated with an inflammatory response. YKL- 40, a novel biomarker for acute and chronic inflammation, has been proved to have a role in these complications. Many classes of antidiabetic drugs may have modulatory effects on inflammation beyond their glucose‐lowering activity. So, inThis study we evaluate comparative effects of metformin and glimepiride on ykl-40 serum level in type2 diabetic patients. Patients and method(s):In a parallel-group, randomized trial setting, 46 newly diagnosed, medication-naïve type 2 diabetes patients were assigned to metformin (in divided doses, 500 -850 mg tablets three times daily) (n = 23) or glimepiride (1-4 mg once daily) (n = 23). Serum concentrations of YKL-40, along with HbA1c were measured at baseline visit and after 4 months. Result(s): Both drugs were equally effective to achieve glycemic control. However, metformin caused more significant reduction in YKL-40 concentrations after 4 months when compared to glimepiride (P < 0.05). Conclusion: /From the present study it is hypothesized that metformin is more effective than glimepiride in reduction of YKL-40 level (inflammatory diabetic complications).
Keywords
Diabetes mellitus; YKL-40; Metformin; Glimepiride; Inflammation
Statistics
Article View: 282
PDF Download: 338